Phase II trial of novel carbidopa/levodopa formulation


A new extended-release formulation of carbidopa/levodopa (CD/LD) appears to be as effective as standard CD/LD in stable patients with Parkinson’s disease, according to the results of a small phase II study (Hinson et al. Clin Neuropharmacol 2009; 32: 189-192).

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page